

## Eminent Healthcare Leader appointed as Independent Non-Executive Chairman for Emyria Ltd

### HIGHLIGHTS

**Strategic Appointment:** Emyria welcomes Mr. Greg Hutchinson as Independent Non-Executive Chairman to bolster the Company's innovative mental health research and development programs

**Extensive Healthcare Leadership:** Greg Hutchinson's tenure as CEO of Sonic HealthPlus and Deputy CEO of Sonic Clinical Services underscores significant expertise in scaling frontline health services and research programs

**New frontier in Psychedelic-Assisted Therapy:** Emyria poised to become a global leader in psychedelic-assisted therapy, following Australia's historic legalisation of MDMA and psilocybin for specified mental health conditions<sup>1</sup>

**Emyria Limited (ASX: EMD)** ("Emyria", or the "Company") focused on developing innovative treatments for mental health and neurological conditions, is pleased to announce the appointment of Greg Hutchinson as Independent Non-Executive Chairman.

Mr. Hutchinson has held leadership roles in rapidly scaling clinical services delivery for over 30 years, spending the last 13 as the CEO of Sonic HealthPlus and Deputy CEO of Sonic Clinical Services, subsidiaries of Sonic Healthcare Limited (ASX: SHL) an S&P/ASX 100 company.

Under Mr. Hutchinson's tenure, Sonic HealthPlus has become the largest provider of occupational and community medical services in Australia with a workforce of over 1,800 employees and contractors operating across more than 40 metropolitan, regional and remote locations in all States and Territories. At any one time, Sonic HealthPlus attends to some 7,000 active clients, ranging from small entities to some of the world's foremost corporations across all industry sectors, as well as large government contracts with major Commonwealth and State agencies.

Mr. Hutchinson is also the deputy CEO and a Director of Sonic Healthcare's clinical services division which encompasses approximately 5,000 employees and 2,500 doctors across some of Australia's leading healthcare businesses.

Notably, Mr. Hutchinson's professional background also encompasses the founding and scaling of innovative clinical delivery care models and commercial activities.

# emyria

*"Joining Emyria is an incredible opportunity to lead in a groundbreaking area of mental health treatment - underpinned by world-class research infrastructure and processes. With Australia's landmark decision to legalise MDMA and psilocybin for therapeutic use, we are at the forefront of a major healthcare revolution."*

*Emyria's track record in advocacy and accessibility for innovative treatments positions us to lead this new space. I am excited to contribute to a business model that not only promises growth but also has a profound impact on patients' lives."*

- **Greg Hutchinson**



Mr. Hutchinson co-founded 5D Clinics, a Perth-based radiation oncology business pioneering radiosurgery with CyberKnife technology. The clinic, renowned for its advanced treatment of malignant and benign tumours, has become a key referral centre for Australian and international patients and is expanding across Australia.

Previously, Mr. Hutchinson founded a successful chain of private physiotherapy clinics across Australia which were eventually acquired by Sonic HealthPlus.

Mr. Hutchinson has served as a Board Member of Tennis Australia since 2015.

Dr. Stewart Washer, who has made invaluable contributions to Emyria as Chairman, will be stepping down to an unpaid advisory role where he will continue to provide strategic support for Emyria.

**Emyria CEO and MD, Dr. Michael Winlo, praised Dr. Washer's leadership:** *"Stewart has been instrumental in our journey so far, laying the foundations of a company committed to personalised therapy and data acquisition to guide the development of innovative treatments to address unmet clinical needs."*

*"We are excited to welcome Greg, whose exceptional track record in founding and scaling clinical operations and healthcare management will be pivotal in our next growth phase, particularly in expanding our MDMA-assisted therapy program."*

This transition comes at a crucial time as Emyria embarks on expanding its mental health treatment portfolio and impact. Having already provided care to over 15,000 patients through its clinical services subsidiary, Emerald Clinics, Emyria's recent acquisition of the Pax Centre<sup>3</sup>, a leading psychological trauma treatment centre, further amplifies its capability for frontline service delivery and evidence-based research. The Company's active clinical trial in MDMA-assisted therapy and the recent arrival of patient-ready drug supply into Australia highlights its preparedness and commitment to developing this novel treatment with an initial focus on patients with Post-Traumatic Stress Disorder ('PTSD') - a condition affecting ~1,000,000 Australians.<sup>2</sup>

# emyria

Mr. Hutchinson's appointment is expected to support the Company's focus on developing scalable delivery models for these new treatments while collecting Real World Data to support ongoing innovation and therapy development. This strategic addition is complemented by the recent appointment of US-based healthcare executive Dr. Mohit Kaushal to the Board <sup>4</sup>, whose background in rapidly scaling, tech-enabled clinical services aligns with Emyria's vision.

Emyria has agreed that, in addition to Director's fees of \$80,000 per annum, Emyria will issue Mr. Hutchinson the following securities under the terms of its employee incentive plan:

- 500,000 Shares as a sign-on incentive; and
- a further 2,500,000 Performance Rights subject to shareholder approval and according to the following vesting schedule:

Performance Rights	Vesting Conditions (10-day VWAP Share Price) *
500,000	\$0.15
1,000,000	\$0.25
1,000,000	\$0.40

\* The vesting conditions will be satisfied upon the volume weighted average price (VWAP) of Emyria's shares meeting or exceeding the target price as calculated over 10 consecutive trading days in which trades in Emyria's shares occurs. The performance rights will expire 4 years from the date of issue.

On the financial front, Emyria is driving initiatives in clinical services revenue growth and cost-efficiencies <sup>5</sup>. The foundational strength of its clinical services business, coupled with its novel drug development programs, positions the Company for both immediate patient impact and potential for long-term returns.

As Emyria enters this new phase of growth, it remains committed to upholding the highest standards of regulatory compliance and patient safety. Shareholders can expect regular updates on the Company's progress and developments under Mr. Hutchinson's leadership.

## References:

1. <https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists>
2. See ASX release 09 October 2023
3. See ASX release 13 September 2023
4. See ASX release 21 August 2023
5. See ASX release 26 October 2023

This release has been approved by the Board of Emyria.

## FOR FURTHER INFORMATION

**Managing Director**  
**Michael Winlo**  
+61 (0) 8 6559 2800  
[mwinlo@emyria.com](mailto:mwinlo@emyria.com)

**Media Contact**  
**Haley Chartres**  
+61 (0) 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

**Corporate Advisor**  
**Sufian Ahmed**  
+61 (0) 412 316 162  
[info@62capital.com.au](mailto:info@62capital.com.au)

**Emyria Limited** is a clinical services and drug development company focused on revolutionising patient outcomes in neuroscience and mental health via a unique business model:

generates

**Emyria Clinics:** Deliver evidence-based and emerging therapies for mental health and other unmet needs across multiple sites (Emerald Clinics and The Pax Centre)

informs


**Emyria Data:** Robust and ethically-sourced Real-World Data gathered with patients and integrated into an advanced data platform powered by Palantir. Emyria data is used to improve Emyria's distinct therapy and drug development programs.

**Emyria Drug Discovery:** One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia seeking new psychedelic-assisted therapies and treatments for neurological diseases.

**Emyria Drug Development:** A suite of unique, highly potent dose forms of Ultra-Pure cannabinoids seeking registration for a range of mental health and neuroscience indications.

## EMYRIA'S INTERACTIVE INVESTOR HUB

[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



**The Pax Centre** specialises in treating individuals grappling with the psychological impacts of traumatic experiences. Our treatment approach is highly personalised, addressing a wide range of mental health issues, from PTSD and depression to anxiety disorders and substance abuse, often stemming from various life traumas.

Complex trauma, characterised by repeated, relational traumatic events often occurring during developmental stages, requires specialised attention due to its pervasive and lasting impact. In these cases, The Pax Centre prioritises early diagnosis and evidence-based treatments.

We also focus on proactive strategies for health expansion and personal growth, empowering our clients with skills and tools to improve wellbeing and performance. At the Pax Centre, we believe in transforming lives through focused, evidence-based mental health care.



Emerald Clinics is an Australian-based, patient-centric clinical service specialising in providing treatments for patients with complex and chronic conditions, where traditional therapies might not have yielded satisfactory results.

Leveraging our deep expertise with unregistered medicines, such as cannabinoids, we strive to pioneer and personalise care for our patients. Our robust, ethically-sourced data collection methods underpin our commitment to improving patient outcomes and advancing healthcare innovation.

**CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS** Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.